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Abstract
An underlying mechanism for multi drug resistance (MDR) is up-regulation of the transmembrane ATP-binding cassette
(ABC) transporter proteins. ABC transporters also determine the general fate and effect of pharmaceutical agents in the
body. The three major types of ABC transporters are MDR1 (P-gp, P-glycoprotein, ABCB1), MRP1/2 (ABCC1/2) and BCRP/MXR
(ABCG2) proteins. Flow cytometry (FCM) allows determination of the functional expression levels of ABC transporters in live
cells, but most dyes used as indicators (rhodamine 123, DiOC2(3), calcein-AM) have limited applicability as they do not
detect all three major types of ABC transporters. Dyes with broad coverage (such as doxorubicin, daunorubicin and
mitoxantrone) lack sensitivity due to overall dimness and thus may yield a significant percentage of false negative results.
We describe two novel fluorescent probes that are substrates for all three common types of ABC transporters and can serve
as indicators of MDR in flow cytometry assays using live cells. The probes exhibit fast internalization, favorable uptake/efflux
kinetics and high sensitivity of MDR detection, as established by multidrug resistance activity factor (MAF) values and
Kolmogorov-Smirnov statistical analysis. Used in combination with general or specific inhibitors of ABC transporters, both
dyes readily identify functional efflux and are capable of detecting small levels of efflux as well as defining the type of
multidrug resistance. The assay can be applied to the screening of putative modulators of ABC transporters, facilitating
rapid, reproducible, specific and relatively simple functional detection of ABC transporter activity, and ready implementation
on widely available instruments.
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Introduction
Multidrug resistance relates to resistance of tumor cells to a
whole range of chemotherapy drugs with different structures and
cellular targets [1]. The phenomenon of multi drug resistance
(MDR) is a well known problem in oncology and thus warrants
profound consideration in therapeutic treatment of cancer. One of
the underlying molecular mechanisms responsible for MDR is the
up-regulation of a family of MDR transporter proteins that lead to
chemotherapy resistance in cancer by actively extruding a wide
variety of therapeutic compounds from the malignant cells. MDR
transporters belong to an evolutionarily conserved family of ATP
binding cassette (ABC) proteins, expressed in practically all living
organisms from prokaryotes to mammals [2]. The same ABC
transporters play an important protective function against toxic
compounds in a variety of cells and tissues, especially in secretory
organs, at the sites of absorption, and at blood-tissue barriers. The
three major multidrug resistance ABC proteins are MDR1 (P-
glycoprotein, ABCB1), multidrug resistance associated protein 1
(MRP1, ABCC1) and BCRP (ABCG2, placenta-specific ABC
transporter, ABCP/breast cancer resistance protein, mitoxantrone
resistance protein, MXR). MDR1 and MRP1 can transport a
variety of hydrophobic drugs, and MRP1 can also extrude anionic
drugs or drug conjugates. Additional members of the MRP/
ABCC family have also been indicated to be involved in cancer
multidrug resistance [for details, see [3]]. The transport properties
of BCRP overlap both with that of MDR1 and the MRP type
proteins, thus these three proteins form a special network involved
with chemo-defense mechanisms.
Because of a significant role that ABC transporters play in cancer
multidrug resistance and the body’s protection against xenobiotics,
sensitive and specific quantitative assays are required for the
detection of the activity of these proteins. Also, higher throughput
assay systems are required to screen for potential transporter-
interacting partners. Estimation of the activity of ABC transporters
is not easily achieved by routinely available classical non-functional
methods, such as Northern blotting, RNase protection, RNA in situ
hybridization, RT-PCR or immunostaining. ABC transporter
protein expression is often not correlated with mRNA levels, as
transcripts are often present below the detection threshold, since
relatively few active transporter molecules can cause major
alterations in drug transport. Additionally, functional activity of
ABC transporters may not correlate with their expression levels
determined by the methods listed above [4].
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pounds against the concentration gradient, across the cell
membrane, has allowed the development of a number of
functional assays to measure their level and function. Upon
loading of the cells with lipophilic dye(s) capable of diffusing across
cell membranes, the resulting fluorescence intensity of the cell(s)
will depend upon the activity of the ABC transporters [5]. The
cells with highly active transporters will display lower fluorescence
intensity values because of the increased efflux of the dye/
substrate. The functions of ABC transporters have been
characterized by measuring the cellular uptake, efflux, or steady-
state distribution of a number of fluorescent substrates using flow
cytometry, fluorescence microscopy or fluorimetry. Substrate
specificities of MDR1, MRP and BCRP transporters are distinct,
but also overlapping [6].
Several drawbacks have been noted relating to the use of most
fluorophores in ABC transporter activity assays arising from
protein binding, dye sequestration, or changes in dye fluorescence
intensity due to changes in intracellular parameters such as pH or
free calcium levels [7]. To increase sensitivity of the method,
hydrophobic ester derivatives, such as acetoxymethyl (AM) esters
of the fluorescent dyes have been employed [8]. These cell
permeable derivatives of fluorescent dyes may be actively exported
from cells by MDR proteins. However, when these ester
derivatives reach the cytosol, intracellular esterases cleave the
ester groups rendering the export of resulting free dye by MDR
proteins in the cells also possible [8,9].
Clinicians are especially interested in identifying the drug
resistance profile, substrate specificity and drug extrusion activity
of the various multi-drug resistance proteins expressed in a given
tumor sample. The demonstration of the transport activity of
various multi-drug resistance proteins in the plasma membrane
requires a sensitive and reproducible in vitro multi-drug resistance
assay. To date, BCRP has gained prominence as one of the three
major ATP-binding cassette (ABC) membrane efflux transporters,
alongside MDR1 and MRP, conferring drug resistance in cancer
and inflammation chemotherapies [10,11,12]. Besides being
present in drug-resistant cancer and T-cells, BCRP is also
endogenously expressed at a high level in human placenta and
to a lesser extent in liver, small intestine, colon, ovary, veins,
capillaries, kidney, adrenal, and lung, with little to no expression in
brain, heart, stomach, prostate, spleen, and cervix [13]. It has been
demonstrated that calcein AM is useful for the quantitative
functional analysis of the presence of active ABCB and ABCC but
not ABCG gene family member transporters in cells [11]. Thus, it
is important to have a simple, reproducible and sensitive method
to determine activity of all three types of ABC transporters in live
cells.
To detect functional activity of drug efflux pumps, two assays
using fluorescent dyes are commonly employed: one measures
cellular dye accumulation and the other measures dye retention.
The accumulation assay measures dye uptake in the presence or
absence of known pump modulators. In the retention assay, the
cells are loaded with the substrate in the absence of any reversal
agent, washed, and then further incubated without dye but in the
presence of reversing agents to allow time for the substrate to be
transported out of the cell by a drug efflux pump. The distinction
between accumulation and retention is necessary when evaluating
cells for MDR phenotypes, as substrates act differently under the
different experimental conditions. Accumulation/retention assays
offer higher throughput, generic readouts (increase in fluorescence
intensity), and are readily automated. However, these assays are
not designed to distinguish MDR1 substrates from inhibitors [14]
and do not directly measure transport.
Thus, there is need for a general non-toxic MDR probe that a)
recognizes all three major ABC transporter’s types in live cells
(unlike the most common MDR probe calcein AM); b) is more
sensitive than commonly used general MDR probes such as
doxorubicin and mitoxantrone; c) can be used in the principal
types of efflux assays discussed above; d) requires few processing
steps and provides a reproducible protocol; e) is compatible with
other common fluorescent dyes used in flow cytometry as well as
diverse fluorescent proteins employed in cells.
Materials and Methods
Dyes and Reagents
eFluxx-IDH Green and Gold multidrug resistance detection kits
were from ENZO Life Sciences, Inc. (Farmingdale, NY). Calcein
AM, 3,39-diethyloxacarbocyanine iodide [DiOC2(3)], chloro-
methylfluorescein diacetate (CMFDA) were obtained from In-
vitrogen Corp. (Carlsbad, CA). Mitoxantrone, doxorubicin,
fumitremorgin C, penicillin, streptomycin, L-glutamine, HEPES,
glucose, sodium piruvate, sodium bicarbonate were obtained from
Sigma-Aldrich Chemical Company (St. Louis, MO). Eagle’s
Minimum Essential Medium with low glucose, F-12K medium,
RPMI-1640 medium, McCoy’s 5A Modified Medium, fetal
bovine serum (FBS) and horse serum were obtained from
American Tissue Culture Collection (ATCC, Manassas, VA). All
components of eFluxx-IDH multidrug resistance detection kits
were prepared according to a manufacturer’s instructions.
Additionally, stock solutions of the following dyes in DMSO were
made: 1 mM (20006) of calcein AM, 20 mg/ml of 3,39-
diethyloxacarbocyanine iodide [DiOC2(3), 10006], 10 mM of
pheophorbide A (20006), 5 mM of chloromethylfluorescein
diacetate (CMFDA, 10006), 10 mM of mitoxantrone (10006)
and 5 mM of doxorubicin (10006). Stock solutions of the dyes
were aliquoted and stored at 220uC in the dark. The following
stocks of additional inhibitors in DMSO were prepared: 5 mM of
cyclosporin A (general specificity inhibitor [15], 10006), 0.2 M of
probenecid (MRP-specific inhibitor, 10006), and 10 mM of
fumitremorgin C (BCRP-specific inhibitor, 10006). Mouse
monoclonal [C219] antibody to P glycoprotein (ab3364), mouse
monoclonal [QCRL1] antibody to MRP1 (ab3369), mouse
monoclonal [MM0047-2J39] antibody to BCRP/ABCG2
(ab72788) and goat polyclonal secondary antibody to mouse IgG
(FITC) (ab6785) were obtained from Abcam Inc. (Cambridge,
MA). The isotype matching control antibodies (mouse monoclonal
IgG2a antibody (ab18414) for [C219] and [MM0047-2J39];
mouse monoclonal IgG1 antibody (ab18448) for [QCRL1]) also
were obtained from Abcam Inc.
Cell lines
Human cervical adenocarcinoma epithelial cell line HeLa
(putative MDR negative cell line), human lung carcinoma cell line
A549 (expression of MPR1 and BCRP [16,17]) and hamster ovary
CHO K1 cell line (expression of all three major ABC transporter
proteins [18,19]) were obtained from ATCC (Manassas, VA).
Human ileocecal colorectal carcinoma cell line HCT-8 (reported
to express MDR1 and, to a lesser extent, MRP [20,21]), human
colorectal adenocarcinoma cell line HCT-15 (reported to over-
express MDR1 [22]) and hepatocellular carcinoma Hep G2
(reported to express MRP [23,24]) were also obtained from
ATCC. Human acute promyelocytic leukemia cell lines HL-60
and HL-60/MX1 (mitoxantrone resistant derivative of the HL-60
cell line) were obtained from ATCC. All cell cultures were
maintained in an incubator at 37uC, with 5% CO2 atmosphere in
appropriate cell culture media as per ATCC recommendations.
Flow Cytometry Assay for Multidrug Resistance
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Cell viability was evaluated by a standard 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay,
as described elsewhere [25]. Viability was calculated as a ratio of
OD595 for treated cells to the OD595 of untreated control cells.
MDR assay (dye uptake protocol)
Detailed protocol for the MDR assay is available in the
Instruction Manual for eFluxx-IDH Green or Gold Multi-Drug
Resistance Assay Kit (ENZO Life Sciences, Inc., Farmingdale,
NY). Briefly, on the day of the assay, cells were collected, washed
with PBS and incubated with or without MDR inhibitors in the
presence of the eFluxx-IDH Green or Gold probes for 30 min at
37uC and analyzed immediately by flow cytometry. eFluxx-IDH
Green or Gold probes are novel xanthene-based small molecule
dyes developed for the detection of MDR activity in living cells. In
order to exclude dead cells in the analyses, propidium iodide (PI)
or 7-actinaminomycin D (7-AAD) solution was added to the cells
during the last 5 min of incubation in some experiments.
To develop a minimal step assay procedure for the dye uptake
protocol, three modifications of the protocol were investigated.
One set of the cells was treated according to a general ‘‘no-wash’’
protocol (see Instruction Manual for the kit). In the second set of
tubes, the reaction was stopped by rapid centrifugation (1 min) at
relatively low speed (2006g). After washing with ice-cold PBS and
discarding the supernatant, cells were re-suspended in 0.5 ml of
ice-cold medium and kept on ice until flow cytometry analysis was
performed. The third set of cells was simply spun down (1 min,
2006g) to remove the excess probe, resuspended in ice-cold
medium and kept on ice until flow cytometry analysis was
performed. eFluxx-IDH Green dye (ex/em 490/514 nm) fluores-
cence intensity was measured in the FL1/FITC (530/30 filter)
channel, and eFluxx-IDH Gold dye (ex/em 530/555 nm)
fluorescence intensity was monitored in the FL2/PE (585/42
filter) channel.
Immunofluorescent flow cytometry MDR assay
Cells (5610
5 per sample) were collected by centrifugation
(adherent cells were trypsinized first), washed with cold PBS, fixed
with 0.25% paraformaldehyde (1 h at 2u to 8uC), permeabilized
with 0.05% Tween 20 (15 min at 37uC), and incubated with
100 mL of corresponding primary antibody (5 mg/mL) overnight.
Post-incubation, cells were washed twice with PBS/0.05% Tween
20, stained with secondary antibody, at 1:5000 dilution, for
30 min at room temperature, washed again, re-suspended in PBS/
2% FBS and analyzed using flow cytometry. Cells stained with
isotype-matched antibody or with secondary antibody only were
used as controls. Results were quantified by using Kolmogorov-
Smirnov statistics [26] and by comparison of the mean
fluorescence for each sample.
Studies of the effect of intracellular pH and Ca
2+/Mg
2+
concentrations on dye signal
Cells were grown and prepared as described before. To study pH
effect on MDR detection, different sets of tubes (with and without
inhibitors) were prepared using cell culture medium titrated using
3 M potassium acetate (pH 5.0) or 1 M Tris (pH 8.0) to obtain
solutions ranged from pH 5.5 to pH 8.0 (original, unmodified
culture medium pH was 7.5). Cells were resuspended in medium of
a certain pH value for 30 min at 37uC before the experiment. To
study Ca
2+/Mg
2+ effect on the MDR detection, four experimental
conditions were used: No Ca
2+/Mg
2+ (EDTA was added to culture
medium to 5 mM final concentration); standard culture medium
with Ca
2+/Mg
2+ (approximately 1 mM of each); high Ca
2+
concentration medium (10 mM Ca
2+/1 mM Mg
2+) and high
Mg
2+ concentration medium (10 mM Mg
2+/1 mM Ca
2+). Cells
were equilibrated in corresponding solutions for 30 min at 37uC,
and all the following procedures were performed under described
conditions.
Flow cytometry
Experiments were performed using a FACS Calibur benchtop
flow cytometer (BD Biosciences, San Jose, CA) equipped with a
blue (488 nm) laser, and the signals were registered in the FITC
(530/30 filter), PE (585/42 filter) and PerCP (670 LP filter)
channels. eFluxx-IDH Green dye fluorescence was measured in the
FL1/FITC channel, and eFluxx-IDH Gold dye fluorescence, in the
FL2/PE channel. Data analysis was performed using FlowJo 8.8.2
software (Tree Star, Inc., Ashland, OR).
Statistical analysis
All of the experiments were performed at least three times.
Results were expressed as mean 6 S.E. Statistical comparisons
were made using an unpaired two-tailed Student’s t-test. A P value
of ,0.05 was considered significant. Flow cytometry data were
analyzed by comparison of median fluorescence, by using
Kolmogorov-Smirnov statistics (D-value) [26] or by calculating
MDR Activity Factor (MAF) values using the following formula:
MAF=100*((MFIinh2MFI0)/MFIinh), wherein MFIinh and MFI0
are the mean fluorescence intensity values measured in the
presence and absence of inhibitor [7].
Results
Demonstration of multidrug resistance in model
mammalian cell lines using an MTT viability assay
To confirm drug resistance of the cell lines used as model
systems in these studies, HeLa, U-2 OS, CHO K1 and A549 cells
were seeded in 96-well plates at a density of 5610
3 cells/well and
24 h later, treated with increasing doses of different drugs that are
commonly used for cancer chemotherapy and are known to be
associated with the phenomenon of MDR (taxol, doxorubicin,
vincristine, mitoxantrone). A standard MTT viability test was
performed 24 and 48 h post-treatment, as described elsewhere
[25]. Viability was calculated as the ratio of OD595 for treated cells
to the OD595 of untreated control cells and presented as a function
of a drug concentration (Figure 1A–D). Data from the MTT tests
confirmed higher chemoresistance of CHO K1 and A549 cells
compared to HeLa cells towards all toxic compounds used in the
study (Fig. 1A–D). U-2 OS, CHO K1 and A549 cell lines were
used as model cell lines demonstrating MDR activity in all
subsequent studies.
Demonstration of multidrug resistance in mammalian
cell lines using immunostaining and flow cytometry
CHO K1, A549, HeLa, HCT-15, HepG2, HL-60 and HL-60/
MX1 cells were collected, fixed and stained with the specific
monoclonal antibodies against MDR1, MRP1 and BCRP
transporters, as described in Materials and Methods. Cells were
analyzed using flow cytometry, mean fluorescence values were
registered for each sample and compared to the mean fluorescence
of isotype antibody stained cells and cells stained with secondary
fluorescence only. Population comparison was performed using
FlowJo software and D-values (Kolmogorov-Smirnov statistical
assay) were calculated for each sample (Table 1). A D-value
greater than 0.2 was considered to be positive [26,27,28].
Flow Cytometry Assay for Multidrug Resistance
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lines express somewhat higher levels of MDR1 (P-gp) protein than
other cell lines tested. CHO K1, A549, HL-60, HL-60/MX1,
HCT-15 and HepG2 cells are positive for MRP1 expression.
CHO K1, A549 and HL-60/MX1 cell lines express BCRP.
Development of a minimal step assay procedure for the
dye uptake flow cytometry protocol
Preliminary experiments (MTT assays) with eFluxx-IDH Green
and Gold probes demonstrated that both probes are not toxic to
the cells (data not shown). To develop a minimal step assay
procedure for the dye uptake protocol, three modifications of the
protocol were investigated, as described in the Materials and
Methods part. Stained cells were analyzed using flow cytometry.
eFluxx-IDH Green dye (ex/em 490/514 nm) fluorescence inten-
sity was measured in the FL1/FITC (530/30 filter) channel, and
eFluxx-IDH Gold dye (ex/em 530/555 nm) fluorescence intensity
was monitored in the FL2/PE (585/42 filter) channel. Mean
fluorescence intensities (MFI) were registered for each probe used
and MAF values were calculated for each sample. Comparison of
MAF values showed no significant difference between the samples
(data not shown). This observation indicates no wash step is
required for performance of the assay.
Experiments with another model cell line (A549) and with the
other tested probe (eFluxx-IDH Gold dye) demonstrated similar
results, allowing one to conclude that in the novel MDR detection
assay, the dye uptake protocol may be simplified and used without
additional washing steps. However, in this case the samples must
be analyzed within a 30 min interval of staining so the excess of
the probe in the extracellular milieu would not affect the transport
kinetics. If an immediate flow cytometry assay is not possible, then
washing and storing on ice is recommended, since according to
literature reports, most ABC transporters are inactive at 4uC
[29,30].
Fluorescent signal does not vary with changes in
intracellular pH or Ca
2+ concentration
To study the effect of pH changes on MDR detection, CHO
K1, A549 and HeLa cells were equilibrated in medium with
different pH values (ranging from 5.5 to 8.0) as described in
Materials and Methods, pretreated with inhibitors or left untreated
and stained with calcein AM, eFluxx-IDH Green or Gold probes
Figure 1. A–D. CHO K1 and A549 cell lines display increased chemoresistance toward the cytotoxic drugs that are mostly
associated with MDR: doxorubicin (panel A), taxol (panel B), vincristine (panel C), and mitoxantrone (panel D). The U-2 OS cell line
demonstrates moderately increased chemoresistance to a few drugs associated to MDR, such as doxorubicin (panel A) and mitoxantrone (panel D).
The HeLa cell line was used as a non-chemoresistant control specimen. Cells were seeded in 96 well plates, treated with the different doses of
indicated drugs, and a standard MTT viability test was performed 1 and 2 days post-treatment. Results are presented as a ratio of the OD595 of treated
cells to the OD595 of the untreated cells.
doi:10.1371/journal.pone.0022429.g001
Flow Cytometry Assay for Multidrug Resistance
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flow cytometry assay. MAF values calculated for CHO K1 cells at
various pH values were not significantly different for all three
probes used in the assay (data not shown). For A549 cells, MAF
values obtained at pH 5.5 were significantly different from the
values obtained within the range of pH 6.0–8.0 for all three dyes.
Uptake of all three dyes at pH 5.5 is also different from the uptake
in the range of pH 6.0–8.0. For HeLa cells, MAF values obtained
using eFluxx-IDH Green and Gold probes, were similar and did
not show any significant activity of ABC transporters. By contrast,
data obtained with calcein AM, showed activity of P-gp and MRP
at the most extreme pH values of 5.5 and 8.0 (data not shown).
To investigate the influence of intracellular Ca
2+/Mg
2+ changes
on MDR detection, cells were equilibrated in media with different
concentrations of calcium and magnesium cations, as described in
the Materials and Methods section and the dye uptake assay was
performed with eFluxx-IDH Green and Gold probes as well as
calcein AM probe (as a control) followed by flow cytometry
analysis and MAF calculation for each experimental condition.
Ten-fold excess of Ca
2+ did not affect the MAF values obtained
with all three dyes compared to the results obtained in standard
media. Similarly, 106 excess of Mg
2+ only slightly altered MAF
values compared to the standard medium for all dyes used, but
these changes could not be considered significant. It should be
noted that the absence of Ca
2+/Mg
2+ in the medium significantly
diminished MAF values for all three dyes. Overall, these
experiments demonstrated that eFluxx-IDH Green and Gold
probe fluorescence is pH-independent within a physiological
range. Ca
2+/Mg
2+ concentrations (up to 10-fold above standard
medium) also do not affect the results of the assay (data not
shown).
Confirmation of substrate specificity for eFluxx-IDH Green
and Gold probes in mammalian cell lines using a flow
cytometry dye uptake protocol
CHO K1, A549 and HeLa cells were grown on tissue culture
dishes and on the day of assay were treated with eFluxx-IDH
Green and Gold probes with and without inhibitors according to
the described dye uptake protocol (Materials and Methods) and
analyzed by flow cytometry. Calcein AM, DiOC2(3) (MDR1-
specific probe, [31]], CMFDA [MRP-specific probe [24]) and
pheophorbide A (BCRP-specific probe [32]) were used as
additional control MDR probes with known substrate specificity.
The specificity of the probes and MAF values obtained as a result
of the test are listed in Table 2.
In CHO K1 cell line, MDR1 expression was detected by all
specific dyes and by eFluxx-IDH probes; MRP expression was
detected by all specific dyes and by both eFluxx-IDH probes;
BCRP expression was detected by pheophorbide A, which is
specific for this ABC transporter, and by eFluxx-IDH Green and
Gold dyes. In A549 cell line, MDR1 expression was not detected
by any specific dye, nor by either eFluxx-IDH probe; MRP
expression was detected by all specific dyes and by eFluxx-IDH
Green and Gold probes; BCRP expression was detected by
pheophorbide A, and by eFluxx-IDH Green and Gold probes. In
the HeLa cell line, no drug resistance was detected with any dye/
inhibitor combination.
To confirm the specificity and selectivity of eFluxx-IDH probes
further, we employed cultured cell lines that over-express a single
transporter and are reported to exhibit multidrug resistance,
HCT-15 (colorectal adenocarcinoma, overexpression of MDR1
[22]), HepG2 (hepatocellular carcinoma, overexpression of MRP
[23,24]), and HL-60/MX1 cell line (acute promielocytic leukemia,
where mitoxantrone resistance is attributed to BCRP overexpres-
sion [33,34]). Additionally, HCT-8 cell line reported to overex-
press both MDR1 and MRP transporters [20,21] was tested.
HCT-8, HCT-15, HepG2, HL-60 and HL-60/MX1 cells were
grown on tissue culture dishes and on the day of assay were
incubated with eFluxx-IDH Green and Gold probes with and
without inhibitors according to the described dye uptake protocol
(Materials and Methods) and analyzed by flow cytometry. Calcein
AM, DiOC2(3) (MDR1-specific probe, [31]), CMFDA (MRP-
specific probe [24]) and pheophorbide A (BCRP-specific probe
[32]) were used as additional control MDR probes with known
substrate specificity. The specificity of the probes and MAF values
obtained as a result of the test are listed in Table 3.
In HCT-15 cell line, MDR1 expression was detected by all
probes used, when cyclosporin A or verapamil were added. In
contrast, MK571 inclusion does not affect fluorescence of either
eFluxx-IDH probe or calcein AM, confirming the absence of active
MRP type transporters in the cell line. In the HepG2 cell line,
MDR1 expression was not detected by any probe. Instead, a
significant MRP expression was detected by all probes used,
including CMFDA, which is specific for MRP type pumps. BCRP
expression was not detected in either cell line, as shown in the
Table 2B (in the presence of novobiocin). In the HL-60/MX1 cell
line, significant fluorescence increase of both eFluxx-IDH probes
and pheophorbide A probe was observed in the presence of
novobiocin and fumitremorgin C (specific BCRP inhibitors). No
drug resistance was detected with any other dye/inhibitor
combination. Calcein AM fluorescence was not changed by the
Table 1. Detection of the expression levels of three major types of MDR proteins in cultured cell lines using immunostaining with
monoclonal antibodies and a flow cytometry assay.
Pgp Staining [C219] MRP1 Staining [QCRL1]
BCRP/ABCG2 Staining
[MM0047-2J39]
CHO K1 0.2960.3 0.5960.2 0.7460.3
A549 0.1260.02 0.6360.3 0.5760.2
HeLa 0.0660.01 0.1060.03 0.1460.01
HL-60 0.1360.07 0.2260.07 0.1760.09
HL-60/MX1 0.1160.05 0.3160.04 0.8360.01
HCT-15 0.2860.2 0.6060.13 0.0760.02
HepG2 0.1860.05 0.5860.06 0.1460.001
Average D values (6 SEM) for three representative experiments are presented.
doi:10.1371/journal.pone.0022429.t001
Flow Cytometry Assay for Multidrug Resistance
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Cell Line MDR Probe Probe Specificity Verapamil Probenecid Fumitremorgin C
CHO K1 Calcein AM MDR1, MRP 63.9 55.3 6.4
eFluxx-IDH Green 75.8 73.7 34.7
eFluxx-IDH Gold 65.6 61.3 32.4
DiOC2(3) MDR1 86.6 2.4 0
Pheophorbide A BCRP 0.7 8.4 22.3
CMFDA MRP 34.3 56.9 0
Calcein AM MDR1, MRP 28.0 19.5 1.3
A549 eFluxx-IDH Green 16.1 38.7 33.7
eFluxx-IDH Gold 12.3 23.1 31.5
DiOC2(3) MDR1 4.2 1.0 0.9
Pheophorbide A BCRP 4.0 14.2 36.0
CMFDA MRP 16.6 27.1 20.7
HeLa Calcein AM MDR1, MRP 13.0 12.2 0.2
eFluxx-IDH Green 9.0 12.9 1.5
eFluxx-IDH Gold 13.9 8.7 5.1
DiOC2(3) MDR1 0 0 0
Pheophorbide A BCRP 0 0.5 5.8
CMFDA MRP 7.6 9.0 11.4
Average MAF values for three representative experiments are provided, with SD not exceeding 10% for each value.
doi:10.1371/journal.pone.0022429.t002
Table 3. Comparison of MDR activity detection in model cell lines overexpressing a single ABC transporter pump using MDR
probes and inhibitors of different specificity.
Cell Line MDR Probe Probe Specificity CsA Ver MK571 Nov
HCT-15 Calcein AM MDR1, MRP 67.262.0 62.962.6 13.562.9 4.362.2
eFluxx-IDH Green 66.267.0 64.466.7 21.162.6 17.163.7
eFluxx-IDH Gold 68.566.6 65.866.0 16.262.6 16.661.7
DiOC2(3) MDR1 71.065.0 69.364.3 4.362.2 0
HepG2 Calcein AM MDR1, MRP 59.062.4 22.062.9 40.764.5 3.060.1
eFluxx-IDH Green 62.964.0 20.361.6 58.863.2 17.361.2
eFluxx-IDH Gold 63.360.8 17.763.2 69.362.3 15.860.6
CMFDA MRP 50.461.3 12.861.3 52.263.8 7.061.7
HCT-8 Calcein AM MDR1, MRP 46.565.1 25.960.9 31.164.7 7.160.4
eFluxx-IDH Green 36.761.5 32.661.5 51.565.0 12.165.2
eFluxx-IDH Gold 33.862.7 29.060.9 48.465.6 3.561.9
DiOC2(3) MDR1 24.760.9 19.163.7 9.861.2 0
CMFDA MRP 43.063.2 21.263.2 39.263.6 0
HL-60 Calcein AM MDR1, MRP 15.262.5 2.561.1 8.061.7 8.661.5
eFluxx-IDH Green 11.862.8 5.260.6 19.962.9 8.563.1
eFluxx-IDH Gold 0.2960.3 14.063.4 15.860.6 7.261.6
Pheophorbide A BCRP 6.561.7 6.860.6 7.661.6 8.561.4
HL-60/MX1 Calcein AM MDR1, MRP 18.262.7 1.660.3 10.861.8 5.961.2
eFluxx-IDH Green 33.163.4 17.868.3 19.061.9 37.562.6
eFluxx-IDH Gold 30.263.4 14.662.9 16.163.8 24.663.9
Pheophorbide A BCRP 22.563.0 7.663.8 10.263.7 23.460.8
Average MAF values + SEM for three representative experiments are provided. Negative MAF values have been replaced with 0.
doi:10.1371/journal.pone.0022429.t003
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BCRP activity or any other ABC transporter activity.
Profiling ABC transporters using eFluxx-IDH Green and
Gold dyes in conjunction with various other specific MDR
probes
CHO K1 cells were grown in tissue culture dishes and on the
day of assay were treated according to a dye uptake protocol and
analyzed by flow cytometry as described in Materials and
Methods. eFluxx-IDH Green and Gold probes, DiOC2(3)
(MDR1-specific probe, [31]), CMFDA (MRP-specific probe
[24]) or pheophorbide A (BCRP-specific probe [32]) were added
to the cells alone or in combination (general dye + specific dye or
general dye + two specific dyes). Dye combinations were selected
to facilitate spectral separation of the fluorescence emission
profiles. The concentrations of the probes are specified in the
Materials and Methods section.
Following 30 min incubation at 37uC, cells were analyzed by
flow cytometry. Cell population profiles were collected directly
without any compensation correction. Additionally, double or
triple stained samples were also collected after electronic
compensation correction using singly stained samples.
Pheophorbide A, which is a specific probe for BCRP, was used
in combination with either green (eFluxx-IDH Green) or orange
(eFluxx-IDH Gold) MDR general probes. In BCRP-expressing
CHO K1 cells, fluorescence decreased in both channels (FL1/
FITC and FL3/PerCP or FL2/PE and FL3/PerCP) if cyclosporin
A (general MDR inhibitor [15]) or fumitremorgin C (specific
BCRP inhibitor [35]) were not present (Table 4). Quantitative
characteristics of the changes in fluorescence (expressed as D- or
MAF values), corresponded to values obtained with single probes.
It is important to note that in the case of dual probe treatment with
eFluxx-IDH Gold dye, compensation corrections were required to
minimize overlap with the other dye spectra. In the cells that were
BCRP-negative but positive for other types of ABC transporters,
red fluorescence intensity was high, while green or orange
fluorescence was dim.
If DiOC2(3) was used in combination with eFluxx-IDH Gold
dye, in MDR1 expressing cells, both dyes are pumped out in the
absence of the inhibitors and cells exhibit decreased fluorescence
in both the FL1/FITC and FL2/PE channels. In MRP or BCRP
expressing cells, only eFluxx-IDH Gold dye was pumped out in the
absence of the inhibitors, and cells showed lower fluorescence in
the FL2/PE but not FL1/FITC channel. According to these
considerations, when both dyes were used in the CHO K1 cell
line, orange fluorescence was bright in all cases when cells were
treated with the inhibitors, but green fluorescence was bright only
in the presence of verapamil (Table 4).
CMFDA could also be used in combination with eFluxx-IDH
Gold dye. In MRP expressing cells, both dyes were pumped out of
the cells in the absence of the inhibitors and cells demonstrated a
decreased fluorescence in both the FL1/FITC and FL2/PE
channels. In MDR1 or BCRP expressing cells, only the eFluxx-
ID
TM Gold was pumped out and fluorescence declined in the
FL2/PE but not FL1/FITC channel. Accordingly, in CHO K1
cells, orange fluorescence was sustained as a bright signal when
specific inhibitors were used, but green fluorescence remained
bright only when the MRP inhibitor (MK-571) was applied.
For triplex probe profiling, eFluxx-IDH Gold dye was employed
as a general specificity probe, and DiOC2(3), CMFDA and
pheophorbide A were employed as specific probes (Table 5).
When DiOC2(3) and pheophorbide A were used in CHO K1
cell line in conjunction with eFluxx-IDH Gold dye, orange (FL2/
PE) fluorescence remained bright after treatment with all
inhibitors used for the experiment. Green (FL1/FITC) fluores-
cence decreased unless cyclosporin A (general MDR inhibitor) or
verapamil (MDR1 inhibitor) was present. Dark red (FL3/PerCP)
fluorescence remained bright only when cyclosporine A (general
MDR inhibitor) or fumitremorgin C (BCRP inhibitor) were
present.
Similarly, with the combination of eFluxx-IDH Gold dye,
CMFDA and pheophorbide A, orange (FL2/PE) fluorescence
remained bright after treatment with all inhibitors used in the
experiment. Green (FL1/FITC) fluorescence decreased unless
cyclosporin A (general MDR inhibitor) or MK-571 (MRP
inhibitor) was present. Dark red (FL3/PerCP) fluorescence
remained bright only when cyclosporin A (general MDR inhibitor)
or fumitremorgin C (BCRP inhibitor) were present.
eFluxx-IDH Green and Gold probes are more sensitive for
MDR activity detection than other commonly used
probes of general specificity
Sensitivity and specificity of eFluxx-IDH Green and Gold
probes, mitoxantrone and doxorubicin were analyzed and
compared using three model cell lines (CHO K1, A549 and
HeLa). Cells were grown in tissue culture dishes and on the day of
Table 4. Examples of multiplex (dual) probe treatment for
MDR activity profiling in the CHO K1 cell line.
Probes
Detection
Channel
D-values Post Inhibitor
Treatment
(compared to uninhibited cells
CsA Verapamil MK-571 FTC
eFluxx-IDH Green FITC 0.94 0.9 0.98 0.56
Pheophorbide A PerCP 0.25 0.14 0.15 0.33
eFluxx-IDH Gold PE 0.89 0.94 0.96 0.51
Pheophorbide A PerCP 0.25 0.11 0.14 0.34
eFluxx-IDH Gold PE 0.84 0.82 0.96 0.44
DiOC2(3) FITC 0.94 0.96 0.13 0.16
eFluxx-IDH Gold PE 0.9 0.94 0.85 0.53
CMFDA FITC 0.49 0.1 0.91 0.06
(Average D values for three representative experiments are provided as
characteristics of MDR, with SD not exceeding 10% for each value).
doi:10.1371/journal.pone.0022429.t004
Table 5. Examples of multiplex (triple) probe treatment for
MDR activity profiling in the CHO K1 cell line.
Probes
Detection
Channel
D-values Post Inhibitor Treatment
(compared to uninhibited cells
CsA Verapamil MK-571 FTC
DiOC2(3) FITC 0.98 0.98 0.13 0.11
eFluxx-IDH Gold PE 0.81 0.91 0.97 0.54
Pheophorbide A PerCP 0.4 0.17 0.13 0.41
CMFDA FITC 0.47 0.10 0.89 0.14
eFluxx-IDH Gold PE 0.93 0.97 0.95 0.64
Pheophorbide A PerCP 0.20 0.18 0.09 0.27
(Average D values for three representative experiments are provided as
characteristics of MDR, with SD not exceeding 10% for each value).
doi:10.1371/journal.pone.0022429.t005
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by flow cytometry, as described in Materials and Methods. The
results of the assay are presented in Figure 2 (representative
experiment) where average D-values from three independent
experimentsaredisplayed. Allfour probeswerecapable ofdetecting
all three major types of ABC transporters, however the eFluxx-IDH
Green and Gold probes generate substantially higher fluorescence
intensity (as shown by D-values), demonstrating they are capable of
providing more sensitive detection of MDR.
Determination of EC50 Inhibitor Values Using eFluxx-IDH
Green and Gold probes and flow cytometry
CHO K1 cells were grown in tissue culture dishes and on the
day of assay were pre-treated with different concentrations of
cyclosporin A (general MDR inhibitor) or left untreated. Then,
cell samples were stained with eFluxx-IDH Green or Gold probes
and analyzed using flow cytometry. Recorded MFI were plotted
against CsA concentrations (Figure 3A), and EC50 (dose at which
50% of multidrug resistance activity is inhibited) was calculated.
The results estimated an EC50 value for CsA of 2 mM when
eFluxx-IDH Green probe was used and 2.7 mM when the Gold
probe was used. The EC50 value obtained using calcein AM was
3 mM. These data agree well with the literature data for inhibitory
activity of cyclosporin A [36].
Similar EC50 detection experiments were performed using cell
lines overexpressing a single transporter and a corresponding
specific inhibitor. We determined EC50 of verapamil using HCT-15
cell line, EC50 of MK571 using HepG2 cell line and EC50 of
novobiocin and fumitremorgin C using HL-60 and HL-60/MX1
cell lines. Fluorescent probes specific for each particular transporter
and calcein AM were employed for comparison. The results are
presented in Figure 3, panels B–D. For verapamil, the EC50 values
obtained using HCT-15 cell lines were 0.22 mM and 0.24 mM
(eFluxxH-ID Green and Gold respectively), and 0.2 mM for both
calcein AM and DiOC2(3) (Figure 3B). EC50 values for MK571
obtained using HepG2 cell line were as follows: 5 mM for both
eFluxxH-ID Green and Gold, 3.7 mM for CMDFA and 3 mM for
calcein AM (Figure 3C). Novobiocin EC50 values were determined
using HL-60/MX1 cell lines as 10.2 mM (eFluxxH-ID Green),
10.3 mM (eFluxxH-ID Gold) and 10.1 mM (pheophorbide A).
Calcein AM can not be used for detection of EC50 values of BCRP
inhibitors in similar systems (Figure 3D). In summary, Figure 3
demonstrates high concordance of the data obtained using probes
known to be sensitive and specific to the assayed MDR transporters.
Compatibility of eFluxx-IDH Green and Gold probes with
propidium iodide (PI) and 7-AAD, the most common
dead cell indicator dyes
CHO K1 cells were grown in tissue culture dishes and on the day
of assay were treatedaccordingto the dyeuptake protocoldescribed
in Materials and Methods. After 30 min incubation with probe, in
the presence or absence of various inhibitors, PI was added to each
sample to a final concentration of 1 mg/mL and samples were
analyzed by flow cytometry as described in Materials and Methods.
Single stained samples (PI only, eFluxx-IDH Green dye only and
eFluxx-IDH Gold dye only) were analyzed to validate data obtained
with the two dye combinations. Data were collected uncompensat-
ed. For comparison, compensation corrections were performed
using unstained cells, PI only stained dead cells and eFluxx-IDH
Green or Gold dye stained cells (in the presence of cyclosporin A or
MK-571 which results in a bright fluorescent signal).
Data presented in Table 4, clearly demonstrate that use of PI
does not affect MDR detection when eFluxx-IDH Green and Gold
dyes are used. In turn, green or orange fluorescence resulting from
the MDR detection does not affect determination of the number of
dead cells in the sample. In certain cases (when the combination of
eFluxx-IDH Gold dye and PI is used, and inhibitor treatment leads
to a significant orange fluorescence intensity increase), compen-
sation corrections are required in order to avoid overestimation of
dead cell staining. Similar results were obtained when 7-AAD,
another common viability stain was used in the experiments (data
not shown).
Multiplexed MDR detection by flow cytometry in U-2 OS
cells expressing green fluorescent protein (GFP) or red
fluorescent protein (RFP)
U-2 OS parental cells and U-2 OS cells expressing an RFP-
tagged mitochondrial targeting sequence of human cytochrome c
oxidase subunit VIII precursor (Marinpharm GmbH, Lucken-
walde, Germany) were treated with or without inhibitors and
stained with eFluxx-IDH Green dye. Comparable cells expressing
a GFP-tagged construct were stained with eFluxx-IDH Gold dye,
as described in the Materials and Methods. To exclude dead cells,
PI solution was added to the cells during the last 5 min of
incubation (final concentration was 1 mg/mL). Single stained
samples of parental U-2 OS cells were prepared with each dye for
compensation correction.
Experiments conducted with GFP-expressing U-2 OS cells
stained with eFluxx-IDH Gold probe and PI demonstrated
feasibility of MDR activity detection in such systems (Table 5A
and 5B). However, compensation corrections were necessary for
accurate estimation of PI positive cells. PI fluorescence (red) does
not interfere significantly with green and orange dye signal and
green signal does not affect red fluorescence, either. However,
orange fluorescence does affect PI measurements significantly
(particularly, when the inhibition of MDR was observed and
orange signal increased significantly). Thus, those samples stained
with eFluxx-IDH Gold dye and PI required electronic compensa-
tion correction. Based upon these results, recommendations are to
use single stained samples for each dye as well as unstained cells in
order to define appropriate electronic compensation settings.
Nevertheless, results obtained for the MDR activity do not depend
upon compensation correction in all cases.
Discussion
We describe two novel probes for functional detection of
multidrug resistant phenotypes in live cells (both suspension and
adherent) by measuring active dye efflux mediated by different
ABC transporter proteins using flow cytometry. The method
involves exposing cells of a biological specimen to a novel
xanthene-based small molecule probe (either eFluxx-IDH Green or
Gold dye) and measuring the amount of fluorescence that
accumulates in the specimen cells compared to control cells (cells
that do not exhibit MDR or cells that have inhibited MDR
activity). Reduced fluorescence accumulation in tested cells
correlates with multidrug-resistance. Using specific inhibitors of
ABC transporters along with the probe allows easy identification
of even small degrees of functional efflux, as well as definition of
the type of multidrug resistance present in the specimen.
No genetically modified cell lines were used as model systems in
the present study, since the levels of MDR activity in these
modified cell lines is much higher than those encountered with
standard clinical samples [4]. Instead, we used a few well-
characterized cell lines as model systems demonstrating MDR
activity in all subsequent studies. The chemoresistance of the
investigated cell lines has previously been reported elsewhere [16–
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with CHO K1, A549 and HeLa cell lines to determine IC50 of
several drugs and to demonstrate their multidrug resistance
profiles. In parallel, immunostaining flow cytometry was employed
to detect levels of specific multidrug resistant proteins in cell lines
used in the study. In general, results of both assays correlated with
the data obtained by using e-Fluxx-IDH probes (and other
commonly used probes for flow cytometry-based MDR detection).
There are a few discrepancies between immunostaining and
fluorescent probe uptake methods. For example, immunostaining
detects quite low levels of MDR1 protein in CHO K1 cell line,
while these cells demonstrated high MDR1 activity in the uptake
assay with calcein AM, DiOC2(3) and both eFluxx-IDH probes.
One of the possible reasons for this is that the physiological
expression level of this transporter is quite close to the detection
threshold of the antibody. Additionally, relatively small changes in
MDR1 expression levels could cause major alterations in drug
transport activity. Another discrepancy between the immunohis-
tochemistry and functional assay results was the relatively high
levels of MRP1 expression in HCT-15 cell line detected with
antibody staining, in contrast none of the probes (calcein AM,
eFluxx-IDH probes, CMFDA) were able to detect MRP activity in
this cell line. A possible explanation for these results is that in this
particular case, the high protein expression levels did not ensure
high activity of the pump (the threshold of an antibody detection is
much higher than the levels of the protein expression that is
necessary to cause changes in the drug transport). The fact that
this particular antibody demonstrated quite high levels of MRP1
staining in all tested cell lines may serve as indirect proof of this
statement.
Figure 3. Concentration-dependent inhibitory effect of various general and specific inhibitors on MDR probes accumulation in
CHO K1 (panel A), HCT-15 (panel B), HepG2 (panel C) and HL-60/MX1 (panel D) cells. The following MDR probes were used: eFluxx-IDH
Green (filled squares), eFluxxH Gold (filled triangles), calcein AM (grey circles), DiOC2(3) (open triangles), CMFDA (open diamonds), pheophorbide A
(filled diamonds). Cells were stained with the indicated probes in the presence of the various concentrations of the appropriate inhibitors. EC50 values
are defined as the concentration of the inhibitor resulting in half-maximum inhibition of dye accumulation.
doi:10.1371/journal.pone.0022429.g003
Figure 2. eFluxx-IDH MDR probes detect all three major types of ABC transporters in a similar manner as doxorubicin and
mitoxantrone probes, but are significantly brighter, providing much higher sensitivity compared with the other dyes. Model cell
lines (CHO K1, panel A, and A549, panel B) were trypsinized, washed with PBS, aliquoted at 5610
5 cells/sample, and treated in triplicates with
different inhibitors (5 mM of cyclosporin A, 20 mM of verapamil, 50 mM of MK-571, or 0.05 mM of novobiocin) or left untreated. Tested probes (eFluxx-
IDH Green, eFluxx-IDH Gold dyes, doxorubicin or mitoxantrone) were added to every sample. The cells were incubated with the dye(s) in the presence
or absence of inhibitors for 30 min at 37uC. Then cells were immediately analyzed by flow cytometry. Population comparison was performed using
Kolmogorov-Smirnov statistics [26]. Clear histograms represent sample fluorescence in the presence of the inhibitor, shaded – without the inhibitor.
The numbers indicate average D-values for each sample from at least three independent experiments, with SD not exceeding 10% for each value.
doi:10.1371/journal.pone.0022429.g002
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probes using several experimental approaches. First, we
compared the new probes with the commonly used classical
probes of known specificity in conjunction with particular
specific MDR inhibitors (Table 2). Although verapamil is known
to inhibit MRP pumps at higher concentrations [36], we used
low concentrations of verapamil that make it more specific for
MDR1. Additionally, experiments with MDR-specific inhibitors
(MK571 and probenecid) were performed to confirm the
specificity of inhibition. As demonstrated in Table 2, eFluxx-
IDH and calcein AM dyes detect similar MDR1 and MRP levels
in CHO K1 cells, and detect only MRP but not MDR1 in A549
cells. In contrast to calcein AM, which is not able to detect
BCRP activity, eFluxx-IDH probes detect significant BCRP
activity in both CHO K1 and A549 cell lines. Results obtained
with eFluxx-IDH probes corroborate the MTT chemoresistance
data (Figure 1A–D) and agree with the published literature
[17,18,19]. For further validation, we employed cultured cell
lines that over-express a single transporter and are reported to
exhibit multidrug resistance, HCT-15 ([colorectal adenocarci-
noma, overexpression of MDR1 [22]), HepG2 (hepatocellular
carcinoma, overexpression of MRP [23,24]), and HL-60/MX1
cell line (acute promielocytic leukemia, presumed overexpres-
sion of BCRP since mitoxantrone resistance is usually attributed
to BCRP overexpression [33]). Additionally, the HCT-8 cell
line, reported to overexpress both MDR1 and MRP transporters
[20,21], was tested. Again, specific inhibitors were utilized, and
classical probes with known specificities were used for the
control treatments (Table 3). The data presented in this table,
were corroborated by the data obtained with an alternative
method of detection of MDR protein expression (Table 1A).
Quantitatively, the results of immunostaining generally demon-
strate good correlation with the results of the functional uptake
assays. The comparison of the data presented in both tables
confirmed that both eFluxx-IDH probes can specifically detect a
particular MDR activity when used together with a correspond-
ing modulator of ABC transporter activity.
The sensitivity of the developed probes is comparable to the
most sensitive commonly used classical MDR detection probes
(like calcein AM, DiOC2(3), CMDFA). EC50 values for various
specific inhibitors detected using eFluxx-IDH probes and cell
lines expressing a single ABC transporter are very close to the
EC50 values detected using the commonly used probes
(Figure 3). From another perspective, unlike the most com-
monly used classical MDR probes, eFluxx-IDH MDR probes
are capable of detecting and distinguishing between all three of
the major types of ABC transporters in live cells: MDR1 (P-
glycoprotein), MRP and BCRP. Importantly, new draft
guidelines from the United States Food and Drug Administra-
tion (FDA) now recommend providing in vitro drug interaction
information on drug efflux transporters, particularly MDR1
and BCRP, for New Drug Application (NDA) filings [37].
Calcein AM is only capable of measuring one of these two key
drug efflux transporters [6,11], while the eFluxx-IDH probes
can simultaneously monitor both.
Using eFluxx-IDH MDR probes offers a rapid, reproducible,
specific and relatively simple way for functional detection of ABC
transporter proteins that allows high-volume specimen throughput
and employs widely available instrumentation. The previously
described classical dye-based uptake protocols include several
washing steps, thus being time- and effort consuming. It is
demonstrated that the washing steps are optional when employing
eFluxx-IDH probes and may be omitted from the uptake protocol
to simplify the assay and make it more user-friendly. However, if
large numbers of samples (over ,60) are to be analyzed
simultaneously, the excess dye should be washed away and
samples kept on ice until the measurement is performed.
Otherwise, samples would have to be analyzed in small batches
to avoid measurement artifacts. The described assay allows
quantification and comparison of multidrug resistance levels
between different samples or cell lines (by calculating MAF values
or using Kolmogorov-Smirnov statistics). eFluxx-IDH probes
demonstrate fast internalization, favorable uptake/efflux kinetics
and much better sensitivity than the commonly used fluorescent
substrates of general specificity, such as doxorubicin and
mitoxantrone (Figure 2).
eFluxx-IDH Green and Gold probes demonstrate performance
similar to or better than calcein AM with respect to pH
independence of signal and can be used in an operational range
of pH 6.0 through 8.0. Differences in fluorescence intensities of
the eFluxx-IDH MDR probes in the described protocol are solely
dependent upon the presence of the ABC transporters and do not
depend upon the activity of cytosolic esterases, pH and
intracellular Ca
2+ concentration (similarly to calcein AM dye,
which calcein-AM is not fluorescent and free calcein is not a
substrate of the multidrug transporter) [7,8].
The 488 nm laser excitable eFluxx-IDH MDR probes are
compatible with a wide range of instruments, and with other
common fluorescent dyes/fluorescent proteins typically used in
flow cytometry. With appropriate compensation correction,
both probes can be used in combination with PI or 7-AAD, the
most common cell viability dyes employed in flow cytometry.
Moreover, their spectral characteristics are compatible with
common dyes used in multicolor flow cytometry experiments
(such as PE), and with different fluorescent proteins such as GFP
and RFP. Additionally, the developed MDR probes can be used
in conjunction with other specific MDR probes (with compatible
spectral characteristics) to facilitate the discrimination of the
type of multidrug resistance in a cell (Tables 4 and 5).
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